Teva Pharma (NYSE: TEVA) announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments Mergers and Acquisitions

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics July 28, 2015 9:23 AM Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO July 28, 2015 8:12 AM Mylan's (MYL) Price Target Reduced to $65 at Deutsche BankJuly 27, 2015 2:34 PM Cowen Downgrades Mylan (MYL) to Market PerformJuly 27, 2015 7:50 AM Mylan (MYL) Comments on Teva/Allergan Deal; Strategic Focus Remains UnchangedJuly 27, 2015 6:43 AM Teva Pharma (TEVA) Prelim. Q2 Revenue, EPS Outpace ViewsJuly 27, 2015 6:14 AM Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock DealJuly 27, 2015 6:03 AM Teva Reports Preliminary Second Quarter 2015 ResultsJuly 27, 2015 4:47 AM Teva Withdraws Proposal to Acquire MylanJuly 27, 2015 4:31 AM